Numab’s billion-dollar antibody deal takes an unexpected turn - European Biotechnology Magazine

Numab’s billion-dollar antibody deal takes an unexpected turn - European Biotechnology Magazine

Just over a year and a half ago, it made headlines: Swiss biotech Numab AG, based in Horgen on Lake Zurich, sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. No back-loaded milestones, no future contingencies — but cash up front, as one might say, straight into the pocket. The post Numab’s billion-dollar antibody deal takes an unexpected turn appeared first on European Biotechnology Magazine.